June 15, 2017
Reston, Va. – More than 5,000 physicians, technologists, scientists and exhibitors gathered for the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) 2017 Annual Meeting, held June 10-14 in Denver, Colorado.
The meeting had more than 700 scientific oral sessions, as well as sessions on new tracers and applications, emerging technologies, a fluciclovine live reader training, updates on appropriate use criteria and coding and reimbursement, and Mo-99 production and availability. Three Meet-the-Author poster sessions were also held, and the Exhibit Hall provided a one-stop showcase for cutting-edge molecular imaging devices, products, and services. The CT and MRI Case Reviews, presented in collaboration with the University of Colorado Denver, included 52 CT studies and 48 MRI case studies.
At this year’s Opening Plenary Session, the focus was on theranostics. The Henry N. Wagner, Jr., MD, Lecture, titled “Theranostics: Looking Back and Moving Forward,” was given by Richard Baum, MD, PhD. Johannes Czernin, MD, editor-in-chief of The Journal of Nuclear Medicine, provided a closer look at what the future of the field promises, if attention is concentrated on precision medicine and patient outcomes.
The society’s new Value Initiative was also introduced at the meeting. It addresses five critical domains that will guide the society’s strategic plan over the next several years: Quality of Practice, Research and Development, Workforce Pipeline, Advocacy, and Outreach.
SNMMI is an international organization that relies on collaboration across borders. This year, the annual meeting’s highlight country was Germany, which is doing cutting-edge research in all aspects of nuclear medicine, including theranostics.
The 2017 Image of the Year went to a team of researchers from the German Cancer Research Center (DKFZ) and University Hospital in Heidelberg. The image clearly demonstrates how combining the advantages of 68Ga-PSMA PET and intraoperative gamma and fluorescence imaging results in better tumor identification before and during surgery.
With the focus always on patients, Patient Education Day is an important part of the annual meeting. Patients and caregivers attended sessions on nuclear medicine advances in diagnosing and treating neuroendocrine tumors, prostate and thyroid cancers, and Alzheimer’s.
SNMMI introduced SNMMI TV this year, with daily coverage of meeting highlights and interviews on topics ranging from theranostics and the Clinical Trials Network to patient advocacy and molecular imaging applications in neurology and cardiology. In addition to showings throughout the meeting, the videos are available on the SNMMI YouTube site.
SNMMI is offering a Virtual Meeting for those who were unable to attend certain sessions or make the trip to Denver. A Virtual Poster hall will also be offered.
The SNMMI 2018 Annual Meeting will take place June 23-27 in Philadelphia, Pennsylvania.
About the Society of Nuclear Medicine and Molecular Imaging
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to raising public awareness about nuclear medicine and molecular imaging, a vital element of today’s medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated and helping provide patients with the best health care possible.
SNMMI’s more than 17,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit www.snmmi.org.